CardioComm Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a leader in consumer heart monitoring, remote patient monitoring, and medical electrocardiogram ("ECG") software solutions, announces that it has elected to rely on Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers and move to semi-annual financial reporting ("SAR"). Coordinated Blanket Order 51-933 allow
Technology, Healthcare and Hospitals, Health
2026-05-08 4:01 PM EDT | CardioComm Solutions, Inc.
Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce a purchase order ("PO") financing arrangement that will establish a revolving source of dedicated capital to support the sourcing, manufacturing, and fulfillment activities of its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The financing will be offered as a non-brokered private placement o
Technology, Biotechnology, Health
2026-05-08 10:30 AM EDT | Restart Life Sciences Corp.
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio
Vancouver, British Columbia--(Newsfile Corp. - May 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the strategic expansion of its internal operations team as the Company accelerates the scaling of its "better-for-you" functional food and Consumer Packaged Goods (CPG) portfolio. To support its growth trajectory, the Company has added a specialized Project Manager to its internal leadership team. Rep
Technology, Biotechnology, Health
2026-05-08 9:00 AM EDT | Restart Life Sciences Corp.
Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authoriza
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-08 7:30 AM EDT | Red Light Holland Corp.
DiagnosTear Technologies Inc. Announces Results of AGM
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general meeting of shareholders (the "AGM") held today. Shareholders approved all matters recommended by management, including: Setting the number of directors at five and electing Yaacov Michlin, Julia Reznick Zilberman, Karin Gurevitz, Igal Kohn a
2026-05-07 5:00 PM EDT | DiagnosTear Technologies Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
WELL Health Delivers Record Q1-2026 with Canadian Clinics Run Rate Exceeding $500M and Revenue Up 25% to $368M
WELL achieved quarterly revenues of $368.3 million in Q1-2026, an increase of 25% as compared to Q1-2025 driven by organic growth, acquisitions and the inclusion of HEALWELL results in WELL's consolidated financial reporting. WELL achieved Adjusted EBITDA(1) of $43.1 million in Q1-2026, an increase of 56% as compared to Q1-2025, representing an Adjusted EBITDA Margin(1) of 12%. Canadian Patient Services revenues(4) increased by 30% to $130
Technology, Computer Software, Healthcare and Hospitals, Health
2026-05-07 4:00 PM EDT | WELL Health Technologies Corp.
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-05-07 7:30 AM EDT | Red Light Holland Corp.
Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the appointment of Lindsay Hamelin as an Independent Director of the Company, effective immediately. Ms. Hamelin brings over 20 years of capital markets and corporate finance experience, with a specific expertise in corporate structuring, mergers and acquisitions, and financing strategies within publi
Technology, Biotechnology, Health
2026-05-07 6:00 AM EDT | Restart Life Sciences Corp.
BUNCHIES Supports The Busyhead Project During Mental Health Awareness Month
Los Angeles, California--(Newsfile Corp. - May 6, 2026) - BUNCHIES, the new golf snack from Hally Leadbetter, today announces a new partnership with The Busyhead Project, a nonprofit mental health organization founded by 2x GRAMMY®-nominated, multi-platinum superstar Noah Kahan that aims to end the sti
Food / Beverages, Sports, Health
2026-05-06 10:00 AM EDT | Bunchies
Functional Brands Inc. Announces Launch of GLP-Squared Injection
Lake Oswego, Portland--(Newsfile Corp. - May 6, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a pioneer in next-generation health and wellness solutions, today announced the official launch of GLP-Squared Injection, its groundbreaking dual-peptide injectable combining Semaglutide and Tirzepatide in a single, synergistic formulation. GLP-Squared is now exclusively available to members of the Company's flagship digital health platform, Tru2u.health. "The introduction
Household / Consumer / Cosmetics, Health
2026-05-06 8:00 AM EDT | Functional Brands Inc.
QScreen AI Integrates Passive Voice Analysis into Multi-Signal Screening Platform - System Now Reads Physiological, Acoustic, and Behavioral Signals Simultaneously in Real Time
Toronto, Ontario--(Newsfile Corp. - May 6, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen"), today announced the full integration of a novel voice analysis engine into its multi-signal screening platform, expanding the system from camera and structured clinical intake into a three-modality real-time screening solution. QScreen now assesses physiological, acoustic and behavioral indicators simultaneously during the same intake workflow using existing microphon
2026-05-06 7:03 AM EDT | QScreen AI Inc.
Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)
Winter Park, Florida--(Newsfile Corp. - May 5, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company based in Winter Park, Florida, dedicated to advancing regenerative therapies for chronic diseases, today announced that its pivotal clinical study on kidney disease has received Institutional Review Board (IRB) approval and has been successfully submitted to ClinicalTrials.gov.
Healthcare and Hospitals, Health
2026-05-05 10:08 AM EDT | Adia Nutrition Inc.
Tersis Technologies Appoints Energy Infrastructure Expert Michael W. Stogner as Strategic Advisor to Accelerate Deployment of SynGenic V3 Platform
Brooksville, Florida--(Newsfile Corp. - May 5, 2026) - Tersis Technologies, Inc. (OTCID: TERS) ("Tersis" or the "Company"), a circular economy technology company focused on converting waste streams into energy and valuable byproducts, today announced the appointment of Michael W. Stogner as Strategic Advisor - Energy Infrastructure, Deployment & Fuel Strategy.
Agriculture, Energy, Alternative Energy, Health
2026-05-05 10:00 AM EDT | Tersis Technologies Inc.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Pittsburgh
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - May 5, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced the addition of Weinstein Imaging Associates in Pittsburgh, Pennsylvania as a new clinical site in its large multi-center observational collection protocol study to advanc
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-05-05 9:00 AM EDT | Breathe BioMedical Inc.
Altrova Health Announces Launch of O-Spray Product Line and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: SSPLF) (FSE: QM4) ("Altrova Health" or the "Company") today announced the introduction of O-Spray™, a needle-free sublingual oral spray dosage format designed as an alternative to self-injection, pill, and syringe-based administration. O-Spray is positioned across current and future therapeutic areas including weight management, erectile dysfunction, menopause-related care, and other
2026-05-05 7:04 AM EDT | Altrova Health Inc.
Promino Responds to Growing Demand for Muscle Health Support as Health Canada Expands Access to Semaglutide
Burlington, Ontario--(Newsfile Corp. - May 5, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition co
Food / Beverages, Sports, Health
2026-05-05 7:00 AM EDT | Promino Nutritional Sciences, Inc.
Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce that Horizon Health ("Horizon") has purchased an additional 100 Venowave™ units. This second commercial order follows the rapid deployment and clinical success of the initial 100-unit shipment delivered to Horizon in la
Technology, Biotechnology, Health
2026-05-05 6:30 AM EDT | Therma Bright Inc.
Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to report a significant revenue milestone for April 2026, marking a period of substantial growth following the integration of Holy Crap Foods Inc. Since completing the acquisition on February 27, 2026, the Company has executed a strategic roadmap focused on stabilizing operations, optimizing channel efficiency, a
Technology, Biotechnology, Health
2026-05-05 6:00 AM EDT | Restart Life Sciences Corp.
Scryb Inc. Changes Name to NorthPalm Capital Corp. and Announces New Trading Symbols
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm Capital" or the "Company") (formerly, Scryb Inc.), is pleased to announce that further to its news release dated April 15, 2026, the Company's common shares will commence trading on the Canadian Securities Exchange under the new name, "NorthPalm Capital Corp." effective at the market open on May 7, 2026 (the "Name Change") and the trading symbol for the Company will cha
Biotechnology, Healthcare and Hospitals, Health
2026-05-04 9:41 PM EDT | NorthPalm Capital Corp.